The blood creatinine-to-cystatin-c ratio (CCR), an indicator of muscle mass and strength, may be a biomarker of treatment response in children with spinal muscular atrophy (SMA), a study in China shows. Increases in the ratio were significantly associated with gains in motor function following long-term treatment with Spinraza (nusinersen). Although…
Discussion
“Do you remember when Dad took us kite flying?” I asked my brother, Gabriel. We were on a train ride home from the Sands Theatre, where we’d just seen an international production of Disney’s live musical, “Beauty and the Beast.” “Nope,” he said. “I thought that was with the…
Discussion
My goal in college was to become a special education teacher. I had a dream work-study job at a nearby elementary school, assisting in two special ed classrooms. My career plan derailed slightly when I married, moved, and resumed studies at a university without a special education department. Several years…
Discussion
For the past two years, my friend Pam and I have attended Night to Shine, a special prom event held in cities around the world on the same night, created by the Tim Tebow Foundation to celebrate and honor people with disabilities. This year it takes place on Feb.
The strength of nerve signals to muscles may serve as a marker of disease severity, and as a means to track responses to Spinraza (nusinersen) treatment, in children with spinal muscular atrophy (SMA), the findings of a new study suggest. The research showed that children with SMA type…
Treatment with a high-dose regimen of Spinraza (nusinersen) was shown to safely improve motor function in children with spinal muscular atrophy (SMA) in the Phase 2/3 DEVOTE clinical trial. Most patients who switched from the originally approved dose to the high-dose regimen experienced improvements in motor function scores,…
Get regular updates to your inbox.
